172 related articles for article (PubMed ID: 7957570)
1. CR1(CD35) and CR2(CD21) complement C3 receptors are expressed on normal human thymocytes and mediate infection of thymocytes with opsonized human immunodeficiency virus.
Delibrias CC; Mouhoub A; Fischer E; Kazatchkine MD
Eur J Immunol; 1994 Nov; 24(11):2784-8. PubMed ID: 7957570
[TBL] [Abstract][Full Text] [Related]
2. Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL.
Delibrias CC; Fischer E; Bismuth G; Kazatchkine MD
J Immunol; 1992 Aug; 149(3):768-74. PubMed ID: 1386093
[TBL] [Abstract][Full Text] [Related]
3. Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV.
Delibrias CC; Kazatchkine MD; Fischer E
Scand J Immunol; 1993 Aug; 38(2):183-9. PubMed ID: 8346417
[TBL] [Abstract][Full Text] [Related]
4. Complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) cooperate in the binding of hydrolyzed complement factor 3 (C3i) to human B lymphocytes.
Leslie RG; Prodinger WM; Nielsen CH
Eur J Immunol; 2003 Dec; 33(12):3311-21. PubMed ID: 14635039
[TBL] [Abstract][Full Text] [Related]
5. Deficiencies of human C3 complement receptors type 1 (CR1, CD35) and type 2 (CR2, CD21).
Kazatchkine MD; Fearon DT
Immunodefic Rev; 1990; 2(1):17-41. PubMed ID: 2164822
[TBL] [Abstract][Full Text] [Related]
6. Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies.
Tsoukas CD; Lambris JD
Eur J Immunol; 1988 Aug; 18(8):1299-302. PubMed ID: 2970972
[TBL] [Abstract][Full Text] [Related]
7. Interaction between Epstein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2.
Hedrick JA; Watry D; Speiser C; O'Donnell P; Lambris JD; Tsoukas CD
Eur J Immunol; 1992 May; 22(5):1123-31. PubMed ID: 1315687
[TBL] [Abstract][Full Text] [Related]
8. Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice.
Takahashi K; Kozono Y; Waldschmidt TJ; Berthiaume D; Quigg RJ; Baron A; Holers VM
J Immunol; 1997 Aug; 159(3):1557-69. PubMed ID: 9233655
[TBL] [Abstract][Full Text] [Related]
9. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes.
Fischer E; Delibrias C; Kazatchkine MD
J Immunol; 1991 Feb; 146(3):865-9. PubMed ID: 1703182
[TBL] [Abstract][Full Text] [Related]
10. Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23.
Frémeaux-Bacchi V; Bernard I; Maillet F; Mani JC; Fontaine M; Bonnefoy JY; Kazatchkine MD; Fischer E
Eur J Immunol; 1996 Jul; 26(7):1497-503. PubMed ID: 8766552
[TBL] [Abstract][Full Text] [Related]
11. Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells.
Carel JC; Frazier B; Ley TJ; Holers VM
J Immunol; 1989 Aug; 143(3):923-30. PubMed ID: 2473114
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of the stimulation of complement receptors CR1 (CD35) and CR2 (CD21) on cell proliferation and intracellular Ca2+ mobilization of chronic lymphocytic leukemia B cells.
Hivroz C; Fischer E; Kazatchkine MD; Grillot-Courvalin C
J Immunol; 1991 Mar; 146(6):1766-72. PubMed ID: 1826011
[TBL] [Abstract][Full Text] [Related]
13. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells.
Kozono Y; Abe R; Kozono H; Kelly RG; Azuma T; Holers VM
J Immunol; 1998 Feb; 160(4):1565-72. PubMed ID: 9469411
[TBL] [Abstract][Full Text] [Related]
14. Activation of human thymocytes after infection by EBV.
Paterson RL; Kelleher CA; Streib JE; Amankonah TD; Xu JW; Jones JF; Gelfand EW
J Immunol; 1995 Feb; 154(3):1440-9. PubMed ID: 7822809
[TBL] [Abstract][Full Text] [Related]
15. Expression and role of CR1 and CR2 on B and T lymphocytes under physiological and autoimmune conditions.
Erdei A; Isaák A; Török K; Sándor N; Kremlitzka M; Prechl J; Bajtay Z
Mol Immunol; 2009 Sep; 46(14):2767-73. PubMed ID: 19559484
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of complement C3 receptors on human astrocytes.
Gasque P; Chan P; Mauger C; Schouft MT; Singhrao S; Dierich MP; Morgan BP; Fontaine M
J Immunol; 1996 Mar; 156(6):2247-55. PubMed ID: 8690915
[TBL] [Abstract][Full Text] [Related]
17. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
[TBL] [Abstract][Full Text] [Related]
18. Analysis of C3b/C3d binding sites and factor I cofactor regions within mouse complement receptors 1 and 2.
Molina H; Kinoshita T; Webster CB; Holers VM
J Immunol; 1994 Jul; 153(2):789-95. PubMed ID: 8021513
[TBL] [Abstract][Full Text] [Related]
19. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
Diefenbach RJ; Isenman DE
J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
[TBL] [Abstract][Full Text] [Related]
20. Human complement regulatory proteins expressed on mouse A9 cells containing a human chromosome 1.
Seya T; Okada M; Hara T; Matsumoto M; Miyagawa S; Oshimura M
Immunology; 1991 Dec; 74(4):719-24. PubMed ID: 1723716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
